297 related articles for article (PubMed ID: 34357379)
21. Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
Wu HT; Zhao XY
Int J Biol Sci; 2022; 18(5):1974-1988. PubMed ID: 35342342
[TBL] [Abstract][Full Text] [Related]
22. SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
Antosova Z; Podzimkova N; Tomala J; Augustynkova K; Sajnerova K; Nedvedova E; Sirova M; de Martynoff G; Bechard D; Moebius U; Kovar M; Spisek R; Adkins I
Front Immunol; 2022; 13():989895. PubMed ID: 36300122
[TBL] [Abstract][Full Text] [Related]
23. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
25. Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Reina-Ortiz C; Constantinides M; Fayd-Herbe-de-Maudave A; Présumey J; Hernandez J; Cartron G; Giraldos D; Díez R; Izquierdo I; Azaceta G; Palomera L; Marzo I; Naval J; Anel A; Villalba M
Oncoimmunology; 2020 Dec; 10(1):1853314. PubMed ID: 33457074
[TBL] [Abstract][Full Text] [Related]
26. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
27. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
Tamura H
Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
[TBL] [Abstract][Full Text] [Related]
28. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Casneuf T; Xu XS; Adams HC; Axel AE; Chiu C; Khan I; Ahmadi T; Yan X; Lonial S; Plesner T; Lokhorst HM; van de Donk NWCJ; Clemens PL; Sasser AK
Blood Adv; 2017 Oct; 1(23):2105-2114. PubMed ID: 29296857
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
30. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
[TBL] [Abstract][Full Text] [Related]
31. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.
Mustafa N; Azaman MI; Ng GGK; Chng WJ
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139103
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
[TBL] [Abstract][Full Text] [Related]
33. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
34. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
Humbel M; Bellanger F; Fluder N; Horisberger A; Suffiotti M; Fenwick C; Ribi C; Comte D
Front Immunol; 2021; 12():645478. PubMed ID: 33828555
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
36. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
[TBL] [Abstract][Full Text] [Related]
38. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
Nishimura N; Terui Y; Hatake K
Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
Ge AY; Huang CY; Banerjee R; Knoche J; Chung A; Arora S; Martin TG; Wolf J; Wong SW; Wiita AP; Shah N
Br J Haematol; 2023 Jun; 201(5):935-939. PubMed ID: 36846905
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]